Undoubtedly motivated by the looming patent expiration of Lantus, Sanofi (SNY) is teaming up with Medtronic (MDT) on developing drug-device combinations and offering care management services for type 2 diabetes patients. Sanofi brings its insulin portfolio to the partnership while Medtronic brings insulin pumps and glucose monitoring devices. Financial terms are not disclosed.
Approximately 382M people worldwide have diabetes. Type 2 comprises as much as 95% (363M) of the total.
The companies already collaborate for Type 1 diabetes in Europe.